The FDA’s April 30 proposal to exclude semaglutide, tirzepatide, and liraglutide from the 503B bulks list was published Wednesday. By Friday, two organized camps had staked out opposing positions on the proposal—the first signal of how the June 30 comment period will be contested. The Partnership for Safe Medicines, a Washington-based patient-safety advocacy coalition, applauded the FDA’s action. The Alliance for Pharmacy Compounding, the primary trade association for compounding pharmacies, said the proposal “does not change the status quo.” Both responses were strategic. Neither was accidental.

How that contest plays out over the 60-day comment window will substantially shape both the final rule and the broader regulatory direction for compounded peptide therapeutics. (Partnership for Safe Medicines; Alliance for Pharmacy Compounding)

What PSM Said

The Partnership for Safe Medicines (PSM) is a coalition of patient-safety groups, pharmacists, and policy organizations focused on supply-chain integrity and counterfeit-drug enforcement. Its statement on the FDA proposal is unambiguously supportive.

PSM’s framing emphasizes patient harm. The organization cites that mass compounding of GLP-1 medications has been linked to “hundreds of adverse events—including sepsis, liver injury, and hospitalizations—as well as recalls involving thousands of contaminated or improperly dosed vials.” With FDA-approved drugs no longer on the agency’s shortage list, PSM argues, “there is no legal or clinical justification” for outsourcing facilities to continue compounding these substances at scale.

The organization announced plans to submit a formal comment to the Federal Register docket before the June 30 deadline and encouraged other patient-safety advocates to do the same. The implication is that PSM will be a coordinating force for safety-focused public comment over the coming weeks.

What APC Said

The Alliance for Pharmacy Compounding (APC) is the trade association representing compounding pharmacies, including both 503A (patient-specific) and 503B (outsourcing facility) operators. Its statement is more measured, more strategically constructed, and—on careful reading—a different kind of pushback than the headline framing suggests.

APC’s central claim is that the proposal “does not change the status quo.” The reasoning: under existing law, 503B compounding of semaglutide and tirzepatide is already limited because the substances are no longer on the FDA shortage list and have not been on the 503B bulks list. The proposal codifies what is, the APC argues, already the practical operational reality.

That framing is a strategic choice. By characterizing the proposal as redundant rather than impactful, the APC avoids fighting the 503B exclusion head-on while preserving advocacy capital for what the trade association cares more about: the 503A pathway, which would not be touched by the FDA’s proposal. The APC noted that during the shortage period, “FDA-registered outsourcing facilities played an important role in helping meet patient needs when commercially available options were unavailable”—language that defends the historical role without picking a fight over current 503B status.

The interpretation is that the compounding industry’s primary advocacy energy will be directed at preserving the 503A pathway, not at reversing the 503B exclusion. Which is a defensible reading of where the industry’s economic interests now sit.

Why the Two Camps Don’t Actually Disagree About the Same Thing

This is where the dynamics get interesting.

PSM and APC are not arguing about the same proposition.

PSM is arguing that 503B-scale compounding of GLP-1s should not be permitted absent a clear safety and clinical-need justification, particularly in the post-shortage environment. PSM’s safety data—hundreds of adverse events, thousands of recalled vials—is specifically about 503B-scale, mass-compounded products and the quality risks that come with industrial production.

APC is arguing that the 503B path was already largely closed and that the FDA’s proposal simply confirms what was already true. APC is not, in its statement, defending mass-compounded GLP-1s on safety grounds. The trade association is conceding the 503B point while protecting the patient-specific 503A pathway that represents the larger share of its membership’s day-to-day business.

The interesting consequence is that the FDA may be more likely to finalize the proposed 503B exclusion than the public framing of “two camps disagreeing” implies. PSM is for it. APC, on careful reading, is not actually fighting it. The remaining opposition will need to come from telehealth providers and 503B outsourcing facilities directly affected by the rule—a smaller, more commercially interested constituency.

What the Comment Period Will Likely Surface

Beyond the PSM and APC positions, expect three additional voices in the docket.

The 503B outsourcing facilities themselves are commercially affected. Some will file comments arguing that limited 503B compounding remains clinically necessary for specific patient populations or in the event of future shortages. Others will simply move on, given that the 503A pathway and the FDA-approved branded products are increasingly the operative supply channels.

Telehealth providers like Hims & Hers, which built business on compounded GLP-1s, are publicly pivoting toward branded FDA-approved products through arrangements like the Novo Nordisk-Hims partnership announced in March 2026. The commercial direction is already shifting. Whether telehealth advocacy organizations file comments in support of preserving 503B options is uncertain.

Members of Congress and patient testimony will engage. Patients who currently rely on compounded GLP-1s for affordability or access reasons will testify, and that testimony will land in the docket. The FDA will read it. Whether the agency adjusts the proposal in response is a separate question.

International Academy of Compounding Pharmacists (IACP), Academy of Anti-Aging Medicine (A4M), and other compounding-adjacent professional organizations may file. The shape of those positions—whether they line up with APC’s “no status quo change” framing or take a stronger defensive posture—will tell us about the broader compounding industry’s read of the regulatory environment.

What This Means for Peptidings Readers

Three honest takeaways.

The 503B exclusion is likely to be finalized substantially as proposed. The organized advocacy is asymmetric: patient-safety groups are publicly endorsing; the leading compounding trade association is not actively fighting. The political and regulatory momentum is on the side of finalization.

The 503A pathway, where most patient-specific compounding actually happens, is not affected by this proposal. Patients currently receiving compounded semaglutide from a 503A pharmacy under physician prescription do not need to act on this news. The 503A vs 503B distinction—covered in our compounding categories explainer—is the operative one.

The next regulatory inflection point in the compounding-and-peptides space is the July 23–24 PCAC meeting on the proposed 503A bulks list inclusion of seven peptides—BPC-157, KPV, TB-500, MOTs-C, DSIP, Semax, and Epitalon. That’s a separate fight, in a different part of the regulatory infrastructure, with different stakes. Our coverage there will be ongoing.

For deeper analysis of the 503A versus 503B distinction and the broader regulatory taxonomy that governs compounded peptides, our forthcoming Behind the Evidence column on the topic—publishing this week—walks through the framework in detail.

References

1. Partnership for Safe Medicines Applauds FDA Action to Curb Unsafe Compounding of GLP-1 Medications. PSM Press Release. May 1, 2026. PSM
2. Statement from the Alliance for Pharmacy Compounding on FDA Proposed Rule Regarding 503B Bulks List. APC. May 2026. APC
3. FDA Proposes to Exclude Semaglutide, Tirzepatide, and Liraglutide on 503B Bulks List. FDA. April 30, 2026.
4. List of Bulk Drug Substances for Which There Is a Clinical Need Under Section 503B. Federal Register. Docket 2026-08552. May 1, 2026.
5. FDA Moves to Permanently Close the Door on Compounded GLP-1s. Pharmacy Times. 2026.